zurück Home | BP-assoziierte Osteonekrose | |||||||||||||||||
allgemeines | MRONJ | Medication-related osteonecrosis of the jaw | ||||||||||||||||
Osteoporose | Biphosphonat-Behandlung | Risiko von MRONJ: 1 pro 10.000 bis 100.000 Patientenjahre (1) | ||||||||||||||||
Knochenmetastasen | ||||||||||||||||||
Grad |
| |||||||||||||||||
Teriparatid | Recombinantes humanes Parat-Hormon | Therapie der Osteoporose. | Fördert die Heilung chronischer Perideontitis | Therapie der MRONJ | ||||||||||||||
Teil von |
Biphosphonate-Therapie | Therapie von Tumorerkrankungen | Onkologie | |||||||||||||||
Quellen |
1.) Khan AA, Morrison A, Hanley DA, et al.: Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus. J Bone Miner Res 2015;30:3-23 2.) Saad F, Brown JE, Van Poznak C, et al.: Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012;23:1341-1347 3.) Hoff AO, Toth B, Hu M, et al.: Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Ann N Y Acad Sci 2011;1218:47-54 4.) Sim I-W, et al.: Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial. J Clin Oncol 2020;38:2971-2980 | |||||||||||||||||
Impressum Zuletzt geändert am 18.06.2021 7:19